Healthcare

CareDx focuses on transplant diagnostics, with most revenue coming from recurring testing services used to monitor organ recipients. Growth and cash flow have improved sharply, and its niche position in transplant care makes the company worth a closer look.

Celcuity is a clinical-stage oncology company centered on gedatolisib, a late-stage breast cancer drug candidate. The appeal comes from a focused strategy in a large cancer market and clear clinical milestones that could reshape the company’s scale.

Brookdale runs one of the largest senior living platforms in the U.S., with most revenue coming from resident fees in independent living, assisted living, and memory care. Demographic demand and improving cash generation make its recovery path worth a closer look.

Amylyx is rebuilding around a focused pipeline after the collapse of its former ALS revenue base. The company stands out for very low debt, meaningful clinical upside tied to avexitide, and exposure to rare diseases where a single successful program can change its trajectory.

Butterfly Network makes handheld ultrasound systems paired with software, aiming to bring imaging closer to the patient. Revenue growth and cash-burn improvement have strengthened the case, while its portable platform and recurring software model keep the company worth a closer look.

Beam Therapeutics is developing precise gene-editing medicines based on base editing, a promising approach that could address disease at its source. Its platform depth, partnerships, and pipeline progress make it a closely watched name in genetic medicine.

Axogen develops products for peripheral nerve repair, led by its Avance nerve graft franchise. Strong revenue growth, improving cash generation, and a much stronger balance sheet have lifted its profile, while broader procedure adoption could shape the next phase.